About Raptor Pharmaceutical (NASDAQ:RPTP)
Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:RPTP
CUSIP75382F10
Phone+1-415-4086200
Debt
Debt-to-Equity Ratio1.33%
Current Ratio3.57%
Quick Ratio3.30%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-43.75%
Return on Equity-77.01%
Return on Assets-15.64%
Miscellaneous
Employees158
Outstanding Shares85,310,000
Raptor Pharmaceutical (NASDAQ:RPTP) Frequently Asked Questions
What is Raptor Pharmaceutical's stock symbol?
Raptor Pharmaceutical trades on the NASDAQ under the ticker symbol "RPTP."
How were Raptor Pharmaceutical's earnings last quarter?
Raptor Pharmaceutical Corp (NASDAQ:RPTP) announced its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The biotechnology company earned $32.05 million during the quarter, compared to analysts' expectations of $28.52 million. Raptor Pharmaceutical had a negative return on equity of 77.01% and a negative net margin of 43.75%. Raptor Pharmaceutical's quarterly revenue was up 37.4% on a year-over-year basis. During the same period last year, the business earned ($0.17) earnings per share. View Raptor Pharmaceutical's Earnings History.
Has Raptor Pharmaceutical been receiving favorable news coverage?
Media headlines about RPTP stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Raptor Pharmaceutical earned a coverage optimism score of 0.14 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.28 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Raptor Pharmaceutical?
Shares of RPTP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Raptor Pharmaceutical's stock price today?
One share of RPTP stock can currently be purchased for approximately $9.00.
How big of a company is Raptor Pharmaceutical?
Raptor Pharmaceutical has a market capitalization of $767.76 million. Raptor Pharmaceutical employs 158 workers across the globe.
How can I contact Raptor Pharmaceutical?
Raptor Pharmaceutical's mailing address is 7 Hamilton Lndg Ste 100, NOVATO, CA 94949-8283, United States. The biotechnology company can be reached via phone at +1-415-4086200.
MarketBeat Community Rating for Raptor Pharmaceutical (RPTP)
MarketBeat's community ratings are surveys of what our community members think about Raptor Pharmaceutical and other stocks. Vote "Outperform" if you believe RPTP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPTP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Raptor Pharmaceutical (NASDAQ:RPTP) Earnings History and Estimates Chart
Raptor Pharmaceutical (NASDAQ RPTP) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/4/2016 | Q216 | ($0.18) | ($0.16) | $28.52 million | $32.05 million | View | Listen |  |
| 5/5/2016 | Q116 | ($0.17) | ($0.17) | $27.17 million | $27.47 million | View | N/A | |
| 2/25/2016 | Q415 | ($0.19) | ($0.17) | $26.08 million | $24.67 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.18) | ($0.18) | $24.25 million | $25.80 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.21) | ($0.12) | $21.40 million | $23.30 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.25) | ($0.24) | $19.10 million | $20.50 million | View | N/A | |
| 2/26/2015 | Q414 | ($0.14) | ($0.25) | $20.12 million | $17.30 million | View | N/A | |
| 11/6/2014 | Q314 | ($0.18) | ($0.04) | $18.90 million | $23.80 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.19) | ($0.15) | $14.58 million | $16.31 million | View | N/A | |
| 5/8/2014 | Q413 | ($0.17) | ($0.20) | $11.81 million | $12.10 million | View | N/A | |
| 3/13/2014 | Q313 | ($0.18) | ($0.19) | $8.99 million | $10.25 million | View | N/A | |
| 11/7/2013 | Q3 2013 | ($0.28) | ($0.29) | $2.45 million | $6.60 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.30) | ($0.30) | $0.10 million | $0.02 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.26) | ($0.32) | | | View | N/A | |
| 3/14/2013 | Q1 2013 | ($0.27) | ($0.37) | | | View | N/A | |
| 1/9/2013 | Q1 2013 | ($0.23) | ($0.26) | $0.25 million | | View | N/A | |
| 11/14/2012 | Q412 | | ($0.20) | | | View | N/A | |
| 7/11/2012 | Q2 2012 | ($0.18) | ($0.20) | | | View | N/A | |
| 4/9/2012 | Q1 2012 | ($0.18) | ($0.19) | | | View | N/A | |
| 1/6/2012 | Q4 2011 | ($0.23) | ($0.25) | | | View | N/A | |
| 8/11/2009 | Q2 2009 | | ($0.65) | | | View | N/A | |
| 5/1/2009 | Q1 2009 | | ($2.26) | | | View | N/A | |
| 3/27/2009 | Q4 2008 | | ($3.21) | | | View | N/A | |
| 11/12/2008 | Q3 2008 | ($3.91) | ($5.82) | | | View | N/A | |
| 8/8/2008 | Q2 2008 | ($5.61) | ($8.04) | | | View | N/A | |
| 5/13/2008 | Q1 2008 | ($5.78) | ($4.20) | | | View | N/A | |
| 3/26/2008 | Q4 2007 | ($5.27) | ($8.81) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Raptor Pharmaceutical (NASDAQ:RPTP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Raptor Pharmaceutical (NASDAQ RPTP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 54.88%
Raptor Pharmaceutical (NASDAQ RPTP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/9/2015 | Suzanne Louise Bruhn | Director | Sell | 18,258 | $12.47 | $227,677.26 | 48,437 | |
| 9/2/2015 | Raymond Anderson | Director | Sell | 4,916 | $12.51 | $61,499.16 | 6,695 | |
| 8/31/2015 | Raymond Anderson | Director | Sell | 8,084 | $12.52 | $101,211.68 | 6,695 | |
| 7/1/2015 | Llew Keltner | Director | Sell | 50,000 | $16.05 | $802,500.00 | | |
| 6/18/2015 | Thomas E Daley | Insider | Sell | 35,000 | $15.00 | $525,000.00 | | |
| 6/10/2015 | Suzanne Louise Bruhn | Director | Sell | 30,000 | $13.45 | $403,500.00 | | |
| 5/4/2015 | Richard L Franklin | Director | Sell | 10,000 | $9.61 | $96,100.00 | | |
| 4/2/2015 | Richard L Franklin | Director | Sell | 10,000 | $10.37 | $103,700.00 | | |
| 3/23/2015 | Christopher M Starr | Director | Sell | 20,033 | $11.62 | $232,783.46 | | |
| 3/2/2015 | Richard L Franklin | Director | Sell | 10,000 | $9.18 | $91,800.00 | | |
| 2/24/2015 | Christopher M Starr | Director | Sell | 30,000 | $9.52 | $285,600.00 | | |
| 2/2/2015 | Richard L Franklin | Director | Sell | 7,109 | $9.20 | $65,402.80 | | |
| 1/22/2015 | Christopher M Starr | Director | Sell | 30,000 | $9.45 | $283,500.00 | | |
| 1/15/2015 | Christopher M Starr | Director | Sell | 30,000 | $9.73 | $291,900.00 | | |
| 1/12/2015 | Raymond Anderson | Director | Sell | 10,000 | $10.58 | $105,800.00 | | |
| 12/22/2014 | Christopher M Starr | CEO | Sell | 30,000 | $9.00 | $270,000.00 | | |
| 12/15/2014 | Christopher M Starr | CEO | Sell | 30,000 | $8.15 | $244,500.00 | | |
| 11/24/2014 | Christopher M Starr | CEO | Sell | 30,000 | $9.97 | $299,100.00 | | |
| 10/22/2014 | Christopher M Starr | CEO | Sell | 30,000 | $10.25 | $307,500.00 | | |
| 9/23/2014 | Christopher M Starr | CEO | Sell | 30,000 | $10.21 | $306,300.00 | | |
| 9/16/2014 | Christopher M Starr | CEO | Sell | 32,896 | $10.60 | $348,697.60 | | |
| 9/10/2014 | Raymond Anderson | Director | Sell | 10,000 | $10.81 | $108,100.00 | | |
| 8/25/2014 | Erich Sager | Director | Sell | 10,000 | $11.01 | $110,100.00 | | |
| 7/7/2014 | Llew Keltner | Director | Sell | 10,000 | $11.21 | $112,100.00 | | |
| 5/13/2014 | Georgia Erbez | CFO | Buy | 16,100 | $7.90 | $127,190.00 | 16,100 | |
| 4/7/2014 | Vijay Samant | Director | Sell | 5,000 | $8.59 | $42,950.00 | | |
| 3/17/2014 | Christopher Starr | CEO | Sell | 19,316 | $10.79 | $208,419.64 | 699,370 | |
| 1/13/2014 | Timothy Walbert | Director | Sell | 5,520 | $15.06 | $83,131.20 | | |
| 1/9/2014 | Thomas Daley | Insider | Sell | 15,000 | $14.17 | $212,550.00 | 39,906 | |
| 1/7/2014 | Llew Keltner | Director | Sell | 10,000 | $13.25 | $132,500.00 | | |
| 1/2/2014 | Richard Franklin | Director | Sell | 10,715 | $13.12 | $140,580.80 | | |
| 12/9/2013 | Vijay Samant | Director | Sell | 5,000 | $13.86 | $69,300.00 | | |
| 11/13/2013 | Timothy Walbert | Director | Sell | 5,521 | $12.44 | $68,681.24 | | |
| 11/4/2013 | Richard Franklin | Director | Sell | 10,715 | $14.88 | $159,439.20 | | |
| 10/15/2013 | Christopher M Starr | CEO | Sell | 25,000 | $13.77 | $344,250.00 | | |
| 10/14/2013 | Suzanne Louise Bruhn | Director | Sell | 2,760 | $13.58 | $37,480.80 | | |
| 10/7/2013 | Vijay Samant | Director | Sell | 5,000 | $14.76 | $73,800.00 | | |
| 9/16/2013 | Christopher Starr | CEO | Sell | 25,000 | $14.21 | $355,250.00 | 699,370 | |
| 9/16/2013 | Erich Sager | Director | Sell | 17,000 | $14.21 | $241,570.00 | 130,727 | |
| 9/13/2013 | Suzanne Louise Bruhn | Director | Sell | 2,760 | $14.07 | $38,833.20 | | |
| 9/9/2013 | Richard L Franklin | Director | Sell | 10,715 | $14.24 | $152,581.60 | | |
| 9/9/2013 | Thomas E Daley | Insider | Sell | 25,000 | $14.28 | $357,000.00 | | |
| 8/30/2013 | Georgia Erbez | CFO | Sell | 7,400 | $13.42 | $99,308.00 | | |
| 12/28/2012 | Raymond Anderson | Director | Sell | 2,000 | $5.50 | $11,000.00 | | |
| 11/26/2012 | Erich Sager | Director | Sell | 11,279 | $5.00 | $56,395.00 | | |
| 9/12/2012 | Raymond Anderson | Director | Sell | 2,000 | $5.50 | $11,000.00 | | |
(Data available from 1/1/2013 forward)
Raptor Pharmaceutical (NASDAQ RPTP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Adamas Pharmaceuticals, Inc.: Substantial Upside For A Misunderstood Drug Maker
seekingalpha.com - November 1 at 3:18 PM |
 | Reviewing Raptor Pharmaceutical Corp (RPTP) and Its Peers
www.americanbankingnews.com - September 24 at 6:18 PM |
| Head to Head Review: Raptor Pharmaceutical Corp (RPTP) vs. Prothena Corporation PLC (PRTA)
www.americanbankingnews.com - August 28 at 2:24 PM |
 | RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendments to Art
biz.yahoo.com - October 31 at 7:29 AM |
 | Horizon Pharma (HZNP) Announces Completion of Raptor Pharma (RPTP) Acquisition
www.streetinsider.com - October 26 at 10:37 AM |
| RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisit
biz.yahoo.com - October 25 at 7:08 PM |
| Horizon Pharma (HZNP) Announces Completion of Raptor Pharma (RPTP) Acquisition - StreetInsider.com
www.streetinsider.com - October 25 at 12:18 PM |
 | How These Biotech Stocks are Faring? -- Raptor Pharma, Amicus Therapeutics, Neuralstem, and Macrocure
www.marketwatch.com - October 21 at 7:10 PM |
| RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - October 20 at 8:37 AM |
| RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
biz.yahoo.com - October 11 at 7:28 PM |
| Horizon Pharma: Another Core Plus Biotech Worth Buying
seekingalpha.com - September 28 at 12:19 PM |
Raptor Pharmaceutical (NASDAQ:RPTP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Raptor Pharmaceutical (NASDAQ:RPTP) Income Statement, Balance Sheet and Cash Flow Statement
Raptor Pharmaceutical (NASDAQ RPTP) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
